

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.

艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT
PHASE III CLINICAL TRIAL OF SERUM-FREE RABIES VACCINE
ACHIEVED SATISFACTORY PHASE RESULTS

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company of the latest business developments of the Group.

On August 3, 2023, the first phase of enrollment and inoculation of 30 adults aged 18-60 for the phase III randomized, blinded and similar vaccine parallel-controlled clinical trial on the freeze-dried human rabies vaccine candidate (serum-free Vero cell) of the Group (“**Serum-free Rabies Vaccine Candidate**”) was initiated at the Mianyang Center for Disease Prevention and Control, Sichuan Province. On the premise that the safety the 30 subjects 0-7 days after immunization was satisfactory upon initial evaluation, the enrollment and inoculation of 30 juveniles aged 10-17 was initiated on August 10. A 7-day safety observation after full inoculation was completed on September 18, and the results showed satisfactory safety from the first dose to 7 days after full vaccination.

Rabies virus is a ribonucleotide-type rhabdovirus that is highly virulent in dogs, cats and other mammals. Infection with such virus can cause rabies, which is an acute infectious zoonotic disease. Specific clinical presentation includes a fear of water, fear of wind, spasms of pharyngeal muscles and progressive paralysis. Once symptoms appear, the fatality rate is nearly 100%. Currently, there is a lack of effective clinical treatment for rabies, and therefore post exposure prevention is crucial, primarily through inoculation of human rabies vaccine and injection of passive immunization agents.

Currently, there is no serum-free rabies vaccine approved for launch in the market. The Serum-free Rabies Vaccine Candidate is prepared by culturing serum-free Vero cells with a fixed strain of the rabies virus, with the absence of serum components as a feature, which can effectively reduce adverse reactions such as allergies and fever upon administration. The construction of the workshop for serum-free rabies vaccine with an annual production capacity of 50 million doses has been completed. If the Serum-free Rabies Vaccine Candidate successfully launches, it will contribute to the eradication of rabies in China and the world.

Meanwhile, investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
AIM Vaccine Co., Ltd.

Mr. Yan ZHOU

*Chairman of the Board, Executive Director
and Chief Executive Officer*

Hong Kong, September 20, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.